Compare IDEXX Laboratories, Inc. (IDXX) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Macy's Inc — how do they compare? IDEXX Laboratories, Inc. trades at $570.95 (market cap $46.22B), while Macy's Inc trades at $23.8 (market cap $6.45B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.2× Macy's Inc's market cap, and Macy's Inc pays a 3.12% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | M | |
|---|---|---|
Market Cap | $46.22B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $26.21 |
52-Week Low | $526.44 | $12.73 |
Enterprise Value | $47.12B | $10.26B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Macy's (M) trades at $24.9, down 1.97% on the day, with a bullish technical signal and strong earnings beat history. The company shows improving fundamentals with net income margin recovery to 2.94% and positive cash flow trends. Recent institutional buying and analyst coverage reflects growing confidence in the turnaround strategy, though revenue declines remain a concern.
The stock presents value opportunity with attractive valuation multiples (P/E 10.13, P/S 0.3) and dividend yield. Upside potential exists to the $30 analyst target, but risks include ongoing revenue pressure and competitive retail environment. The successful execution of 'Bold New Chapter' strategy remains critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
